Skip to content

Multicenter, prospective, randomized, controlled study of the efficacy and safety of claritrebin regimens in reinduction therapy in newly treated children with AML (non-M3)

Multicenter, prospective, randomized, controlled study of the efficacy and safety of claritrebin regimens in reinduction therapy in newly treated children with AML (non-M3)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057563
Enrollment
Unknown
Registered
2022-03-15
Start date
2022-03-17
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric acute myeloid leukemia

Interventions

Group A:IAE
Group B:C+HAG

Sponsors

Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age <18 years old; 2. Non-M3-AML patients diagnosed according to the 2016 revised WHO criteria; 3. Informed consent signed by the child and/or parent or legal guardian; 4. Bilirubin <= (the same age) 3 times the upper limit of normal value; 5. AST and ALT<= (same age) 5 times of the upper limit of normal value; 6. Creatinine <= (same age) 2 times the upper limit of normal value; 7. Good cardiac function, defined as an ejection fraction greater than 50% on echocardiography or MUGA scan.

Exclusion criteria

Exclusion criteria: 1. Acute promyelocytic leukemia, chronic myelocytic leukemia, acute mixed cell leukemia, or known central nervous system leukemia; 2. AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Koch's syndrome, or congenital aplastic anemia; 3. Human immunodeficiency virus (HIV) positive; 4. There is active systemic infection; 5. Any medical history or concomitant disease that the investigator considers to be detrimental to the subject's safe completion of the study; 6. The investigator determines that the subject is medically unfit to receive the study drug or is unfit for any other reason; 7. Known or suspected allergy to the drug under test or to any drug administered in connection with the study; 8. Participated in a drug trial within the past 4 weeks.

Design outcomes

Primary

MeasureTime frame
Complete response rate after reinduction therapy (CR+CRi);

Secondary

MeasureTime frame
Progression-free survival;Objective response rate;Overall survival;Minimal residual disease;Adverse events;Absolute Neutrophil Count;

Countries

China

Contacts

Public ContactZhu Xiaofan

Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences

xfzhu@ihcams.ac.cn+86 13752090418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026